Clinically Relevant Endpoints

Successful drug discovery relies on the selection of drug candidates with good in vivo pharmacokinetic properties, appropriate preclinical safety profiles and data packages supporting on-target effects that can be assessed in multiple animal models. Our Discovery Services group is uniquely poised to aid in these successes. This group is made up of skilled technicians and scientists with decades of experience in big pharma and biotech who collectively have seen hundreds of programs move through the discovery process.

We can guide your research towards a wide array of potential analytical endpoints, including LC-MS, ELISA, immunoassays, clinical chemistry, immunohistochemistry, PCR, cell- and enzyme-based screening, q-NMR whole-body composition, rodent activity and whole-body calorimetry, and many other custom in vivo, in vitro and ex vivo readouts. Simply put, we offer a suite of services to get you a go/no-go answer on your drug discovery program.

You may also be interested in...

Biomarker Services

We can support your drug discovery pipeline by providing biomarker analysis in a non-GxP environment.

Drug Discovery

Learn more about how Charles River’s breadth of drug discovery services can advance your research.